Bank of America Spends $250 Million a Year on GLP-1 Drugs for Employees

Bank of America's chief executive disclosed that the bank spends approximately $250 million a year covering GLP-1 class drugs, including popular weight-loss and diabetes treatments Ozempic and Wegovy, for its employees. Demand for these medications has surged in recent years, with treatment costs for a single patient potentially reaching thousands of dollars annually. Large U.S. employers increasingly face tough decisions about whether to include these drugs in corporate insurance plans, balancing employee health benefits against rapidly rising healthcare costs. For pharmaceutical makers of GLP-1 drugs, such as Novo Nordisk and Eli Lilly, these disclosures reinforce the resilience of corporate-driven demand for their flagship products. Investors should weigh this trend both as a tailwind for obesity-drug makers' stocks and as a growing cost pressure facing a broad swath of corporate America.